Immunogenicity and other problems associated with the use of biopharmaceuticals

Therapeutic Advances in Drug Safety

Volumn 2, Issue 3, 2011, Pages 113-128

  Tovey, Michael G ^a   Lallemand, Christophe ^a  

^a INSTITUT ANDRÉ LWOFF   (France)

Author keywords

adverse events; biopharmaceutical; cytokine; growth factor; immunogenicity; monoclonal antibody

Indexed keywords

EID: 84993811110     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098611406318     Document Type: Review

References (118)

1. Allison M. (2010) PML problems loom for rituxan. Nat Biotechnol 28: 105–106.
2. Alsalameh S. Manger B. Kern P. Kalden J. (1998) New onset of rheumatoid arthritis during interferon beta-1b treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Arthritis Rheum 41: 754–754.
3. Alshekhlee A. Basiri K. Miles J.D. Ahmad S.A. Katirji B. (2010) Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. Muscle Nerve 41: 723–727.
4. Antony G.K. Dudek A.Z. (2010) Interleukin 2 in cancer therapy. Curr Med Chem 17: 3297–3302.
5. Armstrong J.K. Hempel G. Koling S. Chan L.S. Fisher T. Meiselman H.J. (2007) Antibody against poly(ethylene glycol) adversely affects peg-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110: 103–111.
6. Baechler E.C. Batliwalla F.M. Karypis G. Gaffney P.M. Ortmann W.A. Espe K.J. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100: 2610–2615.
7. Barbosa M.D. Vielmetter J. Chu S. Smith D.D. Jacinto J. (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol 118: 42–50.
8. Bates D. (2009) Alemtuzumab. Int MS J 16: 75–76.
9. Bergamaschi R. Montomoli C. (2009) Melanoma in multiple sclerosis treated with natalizumab: Causal association or coincidence?. Mult Scler 15: 1532–1533.
10. Berger J.R. (2010) Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 33: 969–983.
11. Bernatsky S. Renoux C. Suissa S. (2010) Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 69: 1691–1693.
12. Bielekova B. Catalfamo M. Reichert-Scrivner S. Packer A. Cerna M. Waldmann T.A. (2006) Regulatory CD56(Bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103: 5941–5946.
13. Bongartz T. Sutton A.J. Sweeting M.J. Buchan I. Matteson E.L. Montori V. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–2285.
14. Burdick L.M. Somani N. Somani A.K. (2009) Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf 8: 459–472.
15. Calabresi P.A. Giovannoni G. Confavreux C. Galetta S.L. Havrdova E. Hutchinson M. (2007) The incidence and significance of anti-natalizumab antibodies: Results from Affirm and Sentinel. Neurology 69: 1391–1403.
16. Campara M. Tzvetanov I.G. Oberholzer J. (2010) Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation. Expert Opin Biol Ther 10: 959–969.
17. Carroll M.B. Forgione M.A. (2010) Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: A literature review and potential mechanisms of action. Clin Rheumatol 29: 1021–1029.
18. Carson K.R. Evens A.M. Richey E.A. Habermann T.M. Focosi D. Seymour J.F. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood 113: 4834–4840.
19. Casadevall N. Nataf J. Viron B. Kolta A. Kiladjian J. Martin-Dupont P. (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469–475.
20. Castela E. Lebrun-Frenay C. Laffon M. Rocher F. Cohen M. Leccia N.C. (2011) Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis. Arch Dermatol 147: 72–76.
21. Chakravarty E.F. Michaud K. Wolfe F. (2005) Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 32: 2130–2135.
22. Chung C.H. Mirakhur B. Chan E. Le Q.T. Berlin J. Morse M. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358: 1109–1117.
23. Clifford D.B. De Luca A. Simpson D.M. Arendt G. Giovannoni G. Nath A. (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases. Lancet Neurol 9: 438–446.
24. Cohen J.D. Bournerias I. Buffard V. Paufler A. Chevalier X. Bagot M. (2007) Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: A case series. J Rheumatol 34: 380–385.
25. Coles A.J. Compston D.A. Selmaj K.W. Lake S.L. Moran S. Margolin D.H. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801.
26. Content J. (2009) Mechanisms of induction and action of interferons. Verh K Acad Geneeskd Belg 71: 51–71.
27. Costa M.F. Said N.R. Zimmermann B. (2008) Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37: 381–387.
28. Coyle P.K. (2010) The role of natalizumab in the treatment of multiple sclerosis. Am J Manag Care 16: S164–S170.
29. Cunninghame Graham D.S. Akil M. Vyse T.J. (2007) Association of polymorphisms across the tyrosine kinase gene, Tyk2 in UK SLE families. Rheumatology (Oxford) 46: 927–930.
30. Dafny N. Yang P.B. (2005) Interferon and the central nervous system. Eur J Pharmacol 523: 1–15.
31. De Groot A.S. Scott D.W. (2007) Immunogenicity of protein therapeutics. Trends Immunol 28: 482–490.
32. De Santi L. Costantini M.C. Annunziata P. (2005) Long time interval between multiple sclerosis onset and occurrence of primary Sjögren–s syndrome in a woman treated with interferon-beta. Acta Neurol Scand 112: 194–196.
33. Dicato M. Plawny L. (2010) Erythropoietin in cancer patients: Pros and cons. Curr Opin Oncol 22: 307–311.
34. Dietrich L.L. Bridges A.J. Albertini M.R. (2000) Dermatomyositis after interferon alpha treatment. Med Oncol 17: 64–69.
35. Dieude P. Guedj M. Wipff J. Ruiz B. Hachulla E. Diot E. (2009) STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 60: 2472–2479.
36. Dinarello C.A. Bernheim H.A. Duff G.W. Le H.V. Nagabhushan T.L. Hamilton N.C. (1984) Mechanisms of fever induced by recombinant human interferon. J Clin Invest 74: 906–913.
37. Dixon W.G. Hyrich K.L. Watson K.D. Lunt M. Galloway J. Ustianowski A. (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69: 522–528.
38. Duchini A. (2002) Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol 97: 767–768.
39. Fabris P. Floreani A. Tositti G. Vergani D. De Lalla F. Betterle C. (2003) Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 18: 549–558.
40. Fakharzadeh S.S. Kazazian H.H. Jr. (2000) Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 26: 167–171.
41. Farrell R.A. Giovannoni G. (2010) Current and future role of interferon beta in the therapy of multiple sclerosis. J Interferon Cytokine Res 30: 715–726.
42. Felipe V. Hawe A. Schellekens H. Jiskoot W. (2010) Aggregation and immunogenicity of therapeutic proteins. In: Wang W. Roberts C. (eds) Aggregation of Therapeutic Proteins, John Wiley & Sons: Hoboken, NJ.
43. Fernandez-Espartero M.C. Perez-Zafrilla B. Naranjo A. Esteban C. Ortiz A.M. Gomez-Reino J.J. (2011) Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 40: 330–337.
44. Francis G.S. Rice G.P. Alsop J.C. (2005) Interferon beta-1a in MS: Results following development of neutralizing antibodies in prisms. Neurology 65: 48–55.
45. Furst D.E. (2010) The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 39: 327–346.
46. Giovannoni G. (2003) Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Neurology 61: S13–S17.
47. Goodin D.S. Hurwitz B. Noronha A. (2007) Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 35: 173–187.
48. Graham R.R. Kozyrev S.V. Baechler E.C. Reddy M.V. Plenge R.M. Bauer J.W. (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38: 550–555.
49. Gribben J.G. Devereux S. Thomas N.S. Keim M. Jones H.M. Goldstone A.H. (1990) Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335: 434–437.
50. Grossberg S.E. Kawade Y. Grossberg L.D. (2009) The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels. J Interferon Cytokine Res 29: 93–104.
51. Gryta T. (2011) Biogen. Six more cases of brain infection in Tysabri patients. Dow Jones Newswires.
52. Harris J.M. Martin N.E. Modi M. (2001) Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40: 539–551.
53. Hayakawa T. Ishii A. (2011) Japanese regulatory perspective on immunogenicity. In: Tovey M.G. (ed.), Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations, John Wiley & Sons: New York.
54. Heathcote E.J. (1995) Autoimmune hepatitis and chronic hepatitis C: latent or initiated by interferon therapy?. Gastroenterology 108: 1942–1944.
55. Hellquist A. Jarvinen T.M. Koskenmies S. Zucchelli M. Orsmark-Pietras C. Berglind L. (2009) Evidence for genetic association and interaction between the Tyk2 and IRF5 genes in systemic lupus erythematosus. J Rheumatol 36: 1631–1638.
56. Hershberger R.E. Starling R.C. Eisen H.J. Bergh C.H. Kormos R.L. Love R.B. (2005) Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352: 2705–2713.
57. Ismail A. Kemp J. Sharrack B. (2009) Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis. J Neurol 256: 1771–1772.
58. Ito I. Kawaguchi Y. Kawasaki A. Hasegawa M. Ohashi J. Hikami K. (2009) Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 60: 1845–1850.
59. Kappos L. Clanet M. Sandberg-Wollheim M. Radue E.W. Hartung H.P. Hohlfeld R. (2005) Neutralizing antibodies and efficacy of interferon beta-1a: A 4-year controlled study. Neurology 65: 40–47.
60. Kawaguchi Y. Ota Y. Kawamoto M. Ito I. Tsuchiya N. Sugiura T. (2009) Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population. Ann Rheum Dis 68: 1921–1924.
61. Keating G.M. (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70: 1445–1476.
62. Kiladjian J.J. Chomienne C. Fenaux P. (2008) Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22: 1990–1998.
63. Kirshner S. (2011) Immunogenicity of therapeutic proteins: A regulatory perspective. In: Tovey M.G. (ed.), Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations, John Wiley & Sons: New York.
64. Ko J.M. Gottlieb A.B. Kerbleski J.F. (2009) Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 20: 100–108.
65. Kunkel L. Wong A. Maneatis T. Nickas J. Brown T. Grillo-Lopez A. (2000) Optimizing the use of rituximab for treatment of B-cell non-Hodgkin–s lymphoma: a benefit-risk update. Semin Oncol 27: 53–61.
66. Kyogoku C. Morinobu A. Nishimura K. Sugiyama D. Hashimoto H. Tokano Y. (2009) Lack of association between tyrosine kinase 2 (Tyk2) gene polymorphisms and susceptibility to SLE in a Japanese population. Mod Rheumatol 19: 401–406.
67. Lallemand C. Meritet J.F. Blanchard B. Lebon P. Tovey M.G. (2010) One-step assay for quantification of neutralizing antibodies to biopharmaceuticals. J Immunol Methods 356: 18–28.
68. Lallemand C. Meritet J.F. Erickson R. Grossberg S.E. Roullet E. Lyon-Caen O. (2008) Quantification of neutralizing antibodies to human type 1 interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res 28: 393–404.
69. Laroni A. Bedognetti M. Uccelli A. Capello E. Mancardi G.L. (2011) Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci 32: 181–182.
70. Levesque M.C. Ward F.E. Jeffery D.R. Weinberg J.B. (1999) Interferon-beta1a-induced polyarthritis in a patient with the HLA-DRB1*0404 allele. Arthritis Rheum 42: 569–573.
71. Li J. Yang C. Xia Y. Bertino A. Glaspy J. Roberts M. (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98: 3241–3248.
72. Lysandropoulos A.P. Du Pasquier R.A. (2010) Demyelination as a complication of new immunomodulatory treatments. Curr Opin Neurol 23: 226–233.
73. Maini R.N. Breedveld F.C. Kalden J.R. Smolen J.S. Davis D. Macfarlane J.D. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563.
74. Malucchi S. Sala A. Gilli F. Bottero R. Di Sapio A. Capobianco M. (2004) Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 62: 2031–2037.
75. McHutchison J.G. Lawitz E.J. Shiffman M.L. Muir A.J. Galler G.W. McCone J. (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580–593.
76. Meager A. (2006) Measurement of cytokines by bioassays: Theory and application. Methods 38: 237–252.
77. Miceli-Richard C. Comets E. Loiseau P. Puechal X. Hachulla E. Mariette X. (2007) Association of an IRF5 gene functional polymorphism with Sjögren–s syndrome. Arthritis Rheum 56: 3989–3994.
78. Miceli-Richard C. Gestermann N. Ittah M. Comets E. Loiseau P. Puechal X. (2009) The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren–s syndrome. Arthritis Rheum 60: 1991–1997.
79. Minagar A. Alexander J.S. Sahraian M.A. Zivadinov R. (2010) Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opin Biol Ther 10: 421–429.
80. Mira J.A. Lopez-Cortes L.F. Merino D. Arizcorreta-Yarza A. Rivero A. Collado A. (2007) Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther 12: 1225–1235.
81. Monzani F. Caraccio N. Dardano A. Ferrannini E. (2004) Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 3: 199–210.
82. Moore W.V. Leppert P. (1980) Role of aggregated human growth hormone (HGH) in development of antibodies to HGH. J Clin Endocrinol Metab 51: 691–697.
83. Nam J.L. Winthrop K.L. Van Vollenhoven R.F. Pavelka K. Valesini G. Hensor E.M. (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the Eular recommendations for the management of RA. Ann Rheum Dis 69: 976–986.
84. Nordmark G. Kristjansdottir G. Theander E. Eriksson P. Brun J.G. Wang C. (2009) Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren–s syndrome. Genes Immun 10: 68–76.
85. Novick D. Nabioullin R.R. Ragsdale W. McKenna S. Weiser W. Garone L. (2000) The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation. J Interferon Cytokine Res 20: 971–982.
86. O–Neill L.A. Bowie A.G. (2010) Sensing and signaling in antiviral innate immunity. Curr Biol 20: R328–R333.
87. Palucka A.K. Blanck J.P. Bennett L. Pascual V. Banchereau J. (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 102: 3372–3377.
88. Parmiani G. Castelli C. Pilla L. Santinami M. Colombo M.P. Rivoltini L. (2007) Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18: 226–232.
89. Paues J. Vrethem M. (2010) Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. J Clin Virol 48: 291–293.
90. Peyrin-Biroulet L. (2010) Anti-TNF therapy in inflammatory bowel diseases: A huge review. Minerva Gastroenterol Dietol 56: 233–243.
91. Pothlichet J. Niewold T.B. Vitour D. Solhonne B. Crow M.K. Si-Tahar M. (2011) A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol Med 3: 142–152.
92. Powell A. Myles M.L. Yacyshyn E. (2008) The development of systemic sclerosis in a female patient with multiple sclerosis following beta interferon treatment. Clin Rheumatol 27: 1467–1468.
93. Prinz Vavricka B.M. Baumbegrer P. Russmann S. Kullak-Ublick G.A. (2010) Diagnosis of melanoma under concomitant natalizumab therapy. Mult Scler 17: 255–256.
94. Rini B. Wadhwa M. Bird C. Small E. Gaines-Das R. Thorpe R. (2005) Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine 29: 56–66.
95. Ronnblom L. Eloranta M.L. Alm G.V. (2006) The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 54: 408–420.
96. Rosenberg A.S. (2003) Immunogenicity of biological therapeutics: A hierarchy of concerns. Dev Biol (Basel) 112: 15–21.
97. Rudick R.A. Panzara M.A. (2008) Natalizumab for the treatment of relapsing multiple sclerosis. Biologics 2: 189–199.
98. Rueda B. Broen J. Simeon C. Hesselstrand R. Diaz B. Suarez H. (2009) The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 18: 2071–2077.
99. Ryschkewitsch C.F. Jensen P.N. Monaco M.C. Major E.O. (2010) JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 68: 384–391.
100. Schernthaner G. (1993) Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16(Suppl 3): 155–165.
101. Schweighofer C.D. Wendtner C.M. (2010) First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther 3: 53–67.
102. Selmaj K.W. Raine C.S. (1995) Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 45: S44–S49.
103. Sharief M.K. Hentges R. (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325: 467–472.
104. Simin M. Brok J. Stimac D. Gluud C. Gluud L.L. (2007) Cochrane Systematic Review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 25: 1153–1162.
105. Sleijfer S. Bannink M. Van Gool A.R. Kruit W.H. Stoter G. (2005) Side effects of interferon-alpha therapy. Pharm World Sci 27: 423–431.
106. Somani A.K. Swick A.R. Cooper K.D. McCormick T.S. (2008) Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 144: 1341–1349.
107. Stone J.H. (2005) Etanercept plus standard therapy for Wegener–s granulomatosis. N Engl J Med 352: 351–361.
108. Suarez-Gestal M. Calaza M. Dieguez-Gonzalez R. Perez-Pampin E. Pablos J.L. Navarro F. (2009a) Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. Arthritis Rheum 60: 2558–2564.
109. Suarez-Gestal M. Calaza M. Endreffy E. Pullmann R. Ordi-Ros J. Domenico Sebastiani G. (2009b) Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. Arthritis Res Ther 11: R69–R69.
110. Tak P.P. Rigby W.F. Rubbert-Roth A. Peterfy C.G. Van Vollenhoven R.F. Stohl W. (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the Image Trial. Ann Rheum Dis 70: 39–46.
111. Unoki H. Moriyama A. Tabaru A. Masumoto A. Otsuki M. (1996) Development of Sjögren–s syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. J Gastroenterol 31: 723–727.
112. Valentine A.D. Meyers C.A. Kling M.A. Richelson E. Hauser P. (1998) Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25: 39–47.
113. Van Beers M.M. Sauerborn M. Gilli F. Brinks V. Schellekens H. Jiskoot W. (2010) Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res 27: 1812–1824.
114. Wada M. Marusawa H. Yamada R. Nasu A. Osaki Y. Kudo M. (2009) Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. J Viral Hepat 16: 388–396.
115. Wadhwa M. Skog A.L. Bird C. Ragnhammar P. Lilljefors M. Gaines-Das R. (1999) Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 5: 1353–1361.
116. Weiner G.J. (2010) Rituximab: mechanism of action. Semin Hematol 47: 115–123.
117. Wynn D. Kaufman M. Montalban X. Vollmer T. Simon J. Elkins J. (2010) Daclizumab in active relapsing multiple sclerosis (choice study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 9: 381–390.
118. Yilmaz S. Cimen K.A. (2009) Pegylated interferon alpha-2b induced lupus in a patient with chronic hepatitis B virus infection: case report. Clin Rheumatol 28: 1241–1243.